Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
CAPR has been in the news recently: Capricor Therapeutics has experienced a 15% increase in revenue this quarter, attributed to robust sales and customer growth. Additionally, Vinay Prasad, who was appointed as the director of the FDA's Center for Biologics Evaluation and Research (CBER) in May, resigned after three months in the position.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
